Linapride D 10mg/5mg Tablet is a fixed-dose combination medication containing Dapagliflozin 10mg and Linagliptin 5mg, indicated for the management of type 2 diabetes mellitus. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, promotes renal glucose excretion by inhibiting glucose reabsorption in the proximal renal tubules, thereby reducing plasma glucose levels. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. This dual mechanism addresses hyperglycemia through complementary pathways, improving glycemic control in patients inadequately managed by diet, exercise, or monotherapy. Linapride D is typically prescribed as an adjunct to lifestyle modifications and may be used alone or in combination with other antidiabetic agents. The medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe renal impairment. Common adverse effects include urinary tract infections, genital infections, nasopharyngitis, and hypoglycemia when combined with insulin or insulin secretagogues. Regular monitoring of renal function and blood glucose levels is recommended during therapy. Linapride D offers a convenient once-daily oral regimen aimed at optimizing glycemic control while minimizing the risk of hypoglycemia.